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Abstract 18 
 19 
Exon 11 KIT mutations are found in a majority of gastrointestinal stromal 20 
tumours (GIST) and are usually predictive of response to imatinib, a KIT, 21 
PDGFRA and ABL inhibitor. Exon 11 mutations with poor sensitivity to 22 
imatinib and poor outcome can be observed on rare occasions, including 23 
p.(L576P). In silico and in vitro studies suggested a decreased binding affinity 24 
for imatinib in p.(L576P) KIT mutations, thereby offering an explanation for 25 
their poor outcome and poor response to standard therapy. These 26 
observations were further corroborated with anecdotal case reports of 27 
refractoriness or non-durable response to imatinib therapy. However, we 28 
describe the favourable response to imatinib and outcome in five p.(L576P)-29 
KIT mutant GIST patients treated at a tertiary sarcoma referral center. The 30 
sensitivity of p.(L576P)-KIT mutations to imatinib, and the prognostic impact of 31 
this mutation need to be further evaluated in a larger cohort. Based on our 32 
observations, p.(L576P) mutated GISTs should be treated with standard first 33 
line imatinib therapy.  34 
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Abbreviations list 49 
GIST: Gastrointestinal stromal tumors 50 
HPF: High power field 51 
CE-SSCA: Capillary electrophoresis single-strand conformation analysis 52 
RECIST: Response Evaluation Criteria In Solid Tumors 53 
 54 
Introduction 55 
A majority of gastrointestinal stromal tumours (GISTs) harbour KIT activating 56 
mutations, leading to constitutive ligand-independent activation of the tyrosine 57 
kinase receptor and subsequent tumor growth.1 The introduction of imatinib, a 58 
PDGFRA, ABL and KIT inhibitor, has revolutionized systemic therapy and 59 
dramatically impacted survival.2-4 As molecular profiling of GISTs is routinely 60 
incorporated into practice, an increasing number of mutations are being 61 
discovered. The most common mutations are found in exon 11 and affect the 62 
juxtamembrane domain of KIT, which prevents the activation loops from 63 
adopting an active conformation.5 The end result is receptor dimerization in 64 
the absence of a ligand.  Described mutations include single or combination 65 
substitutions, in-frame deletions and insertions. Exon 11 mutations are usually 66 
predictive of imatinib sensitivity with some exceptions. Among these is the 67 
rare missense mutation c.1727T>C leading to p.(L576P). An initial report 68 
suggested that this KIT mutation is associated with an aggressive clinical 69 
course and poor sensitivity to imatinib, which was further corroborated with in 70 
silico studies.6 Recently, a large retrospective study on the clinical 71 
significance of KIT mutation, demonstrated a favourable relapse-free survival 72 
in patients with the p.(L576P) mutation.7 Our experience at the Royal 73 
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Marsden also further supports the favourable prognosis of this subset of 74 
patients in addition to observing sensitivity to imatinib. We hereby describe 75 
the favourable outcome and response to imatinib therapy in five patients 76 
diagnosed with a p.(L576P) KIT mutated GIST.     77 
 78 
Patients and methods 79 
The histological diagnosis of GIST was confirmed by a soft tissue pathologist 80 
and by immunohistochemical staining of CD117 and DOG1 (K.T). For 81 
resected GISTs, the largest tumour diameter and mitotic count per 50 high-82 
power fields (HPF) were evaluated after surgery to establish a risk category 83 
according to the Miettinen and Lasota risk stratification model.8 Molecular 84 
analysis for KIT and PDGFRA mutations were carried on formalin-fixed 85 
paraffin embedded samples using capillary electrophoresis single-strand 86 
conformation analysis (CE-SSCA) followed by confirmation using bi-87 
directional Sanger sequencing. Prior to commencing this study approval was 88 
obtained from the institutional review board and local ethics committee. A 89 
retrospective search of a prospective database was performed to identify 90 
GIST patients with KIT p.(L576P) mutations. 91 
 92 
Case 1. 93 
A 74 year old woman initially presented in 2009 with anemia and weight loss 94 
and was subsequently diagnosed with a localised gastric GIST. The patient 95 
proceeded to a partial gastrectomy in March 2009. Pathology review identified 96 
an 8.5 cm gastric GIST with a mitotic count of 20 per 50 HPF, corresponding 97 
to a high-risk category according to the Miettinen classification. Molecular 98 
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analysis confirmed the p.(L576P) KIT mutation. The patient was offered 99 
adjuvant imatinib (400 mg once a day) therapy for a 3 year period but 100 
declined. The patient was put on active surveillance and remains with no 101 
evidence of disease recurrence 6 years since her initial diagnosis.    102 
Case 2. 103 
A 54 year-old man, diagnosed with chronic lymphocytic leukemia was found 104 
to have a 7 cm mass outside the posterior wall of the bladder on routine 105 
surveillance. An initial biopsy in 2009 complicated by haemorrhage led to an 106 
emergency laparotomy with morcellation of the mass. Histopathology 107 
examination documented the presence of a > 5 cm GIST with a mitotic count 108 
of > 5/50 HPF, classified as high risk. Mutational analysis confirmed the 109 
p.(L576P) KIT mutation. The patient was commenced on imatinib 400 mg 110 
once a day with a subsequent good radiological response and near complete 111 
remission. In 2011, resection of residual disease was attempted, but failed 112 
due to multiple adherences. No residual tumor was found on histological 113 
examination. The patient continues on imatinib and remains well with no 114 
measurable disease on his latest scan (March 2015), six years since his initial 115 
diagnosis. 116 
Case 3. 117 
A 46 year old man was diagnosed in November 2012 with a locally advanced 118 
rectal GIST involving the prostate. Biopsy and subsequent mutational analysis 119 
confirmed the presence of a GIST with infrequent mitoses and the p.(L576P) 120 
KIT mutation. Pelvic exenteration was deemed necessary to resect the 121 
primary tumor. The patient was therefore put on neo-adjuvant imatinib 400 mg 122 
once a day. Fourth months later, the tumor had a marginal decrease in size 123 
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but remained stable by Response Evaluation Criteria In Solid Tumors 124 
(RECIST) criteria. In June 2013, imatinib was subsequently increased to 400 125 
mg twice a day. Two months following the increase, the disease remained 126 
stable. Based on in vitro data concerning the p.(L576P) mutation, the patient 127 
was switched to dasatinib 50 mg twice a day. Repeat imaging continued to 128 
show stable disease, although there was a marginal decrease in the 129 
component of the tumour involving the prostate. On last-follow up, the patients 130 
remains on dasatinib and maintains stable disease, 3 years following his initial 131 
diagnosis. 132 
Case 4. 133 
A 28 year-old man presented with abdominal distension and gastrointestinal 134 
bleeding in October 2013. Imaging showed a large duodenal mass measuring 135 
9 cm with multiple liver deposits. Core biopsies and molecular analysis 136 
confirmed a p.(L576P) KIT GIST with a low mitotic count (< 5 per HPF). The 137 
patient was put on imatinib 400 mg once a day and obtained a partial 138 
response by RECIST on subsequent imaging. A response plateau was 139 
reached in May 2014. Because of the possibility of obstruction if there were 140 
progression of the primary tumor, the patient underwent a Whipple’s 141 
procedure in June 2015. On pathological examination, 20% of the tumour 142 
remained viable. The patient remains well with RECIST stable disease on 143 
imatinib therapy, 2 years since his initial diagnosis. 144 
Case 5. 145 
A 59 year-old woman experienced bloating and fatigue and was found to have 146 
a localised 14 cm gastric GIST in 2009. On biopsy, no definite mitoses were 147 
identifiable. Initial mutational analysis was not done. The patient was started 148 
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on neo-adjuvant imatinib 400 mg once a day, but had poor compliance 149 
because of significant toxicity. Five months after the start of therapy, the 150 
disease was stable by RECIST and subsequently underwent distal subtotal 151 
gastrectomy, right extended hemicolectomy and omentectomy. The post-152 
operative specimen documented an abundant amount of necrosis (>50%) and 153 
a mitotic index of 8/50 per HPF, thereby classifying the disease as high risk. 154 
Mutational analysis confirmed the presence of the p.L576 KIT mutation. 155 
Because imatinib was initially poorly tolerated, she was not offered adjuvant 156 
therapy but instead was put on surveillance. The patient remains free of 157 
disease, now 6 years following her initial diagnosis.  158 
Discussion 159 
Our experience has demonstrated that p.(L576P) KIT mutated GISTs can 160 
respond to imatinib therapy and in addition are associated with favourable 161 
outcome, further supporting the findings by Joensuu et al.9 These 162 
observations contrast with the poor response to imatinib and negative 163 
outcome in 2 patients described by Conca et al.6 and 1 patient described by 164 
Antonescu et al.10 In silico studies suggest that the p.(L576P) mutation 165 
induces conformational change similar to the active form of native KIT thereby 166 
explaining the decreased binding affinity of imatinib. In vitro drug testing on 167 
KIT p.(L576P) mutated anal melanoma cell lines also demonstrated that a 10-168 
fold higher dose of imatinib is required to observe drug sensitivity compared to 169 
KIT imatinib sensitive mutations in addition to showing that dasatinib was 170 
particularly active.11 However, in vivo responses to imatinib therapy were 171 
observed in melanoma patients harbouring the L576P mutation thereby 172 
demonstrating that in vitro testing does not necessarily correlate with in vivo 173 
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experience.12 Furthermore, it is difficult to draw direct conclusions on drug 174 
sensitivity in p.(L576P) KIT mutated GISTs based on p.(L576P) KIT mutated 175 
anal melanoma cell lines. In addition, in our experience, no significant 176 
increase in radiological response was observable after switching from imatinib 177 
to dasatinib therapy in Case 3 despite in vitro data indicating increased drug 178 
activity. Finally, the adverse outcome and poor response to imatinib 179 
previously reported in anecdotal cases of p.(L567P) KIT mutated GIST may 180 
be related to alternative activating signalling pathways, mutations and host 181 
factors responsible for primary resistance. Commonly, early resistance to 182 
imatinib is observed in KIT exon 9, PDGFR, and wild-type GIST.13 However, 183 
in recent years, additional mechanisms responsible for primary resistance in 184 
KIT exon 11 GIST have come to light. Variable interindividual drug 185 
metabolism may contribute to lower imatinib plasma levels and subsequent 186 
clinical responses in a subset of patients with KIT exon 11 GIST.14  187 
Furthermore, concomitant activating mutations in KRAS and BRAF genes 188 
were also involved in documented cases of primary resistance in KIT sensitive 189 
mutated GIST.15 Finally, overexpression of CCND2 and EGFR, impaired p53, 190 
p16, BCL2, CHK2 expression, and silencing of CDKN2A, CDKN2C, 191 
SMARCB1, PTEN and DMD may all variably contribute to acquired resistance 192 
to imatinib therapy.16-18 Further work is needed to elucidate the role of these 193 
alternative signalling pathways. 194 
Based on our observations, standard dose imatinib may be sufficient to 195 
induce a response in p.(L576P) KIT mutated GIST, however, the number of 196 
patients is small and needs to be correlated with a larger series. In vitro drug 197 
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sensitivity screens on p.(L576P) KIT induced mutated GIST cell line would be 198 
helpful to better understand KIT tyrosine kinase inhibitor activity.   199 
 200 
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 202 
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